100% acquisition of stake and strike off Aspira DNA Diagnostics Gujarat LLP, an associate LLP of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics' board, on May 16, 2025, approved acquiring 100% stake in its associate LLP, Aspira DNA Diagnostics Gujarat LLP, and then striking off (winding up) the LLP. The associate contributed Rs 1.15 crore in turnover, about 5.23% of the company's total revenue, and had a negative net worth of Rs 4.31 lakhs, making it a small, loss-making unit. The transaction qualifies as a related party deal, and the assets of the LLP are expected to be taken over by the parent company. The actual agreement execution date, consideration amount, and completion timeline have not been disclosed yet — only the board's in-principle approval has been communicated.
This is a small, internal group consolidation move — absorbing a loss-making associate with minimal turnover share. Neutral to slightly positive for shareholders as it simplifies the group structure, but not material enough to move the stock meaningfully. Investors should watch for the deal consideration and completion details.